A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Who can participate
Inclusion Criteria:
* Men or women greater than or equal to 18 years old.
* ECOG ≤ 1
* Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment
Exclusion Criteria:
* Active brain metastases
* Myocardial infarction within 6 months of study day 1
* Gastrointestinal (GI) tract disease causing the inability to take oral medication
Locations
20
Australia (1)
Blacktown Hospital
Blacktown , New South Wales
Belgium (1)
Institute Jules Bordet
Brussels
Brazil (1)
Hospital de Caridade de Ijui
Ijuí , Rio Grande do Sul
Canada (1)
Tom Baker Cancer Centre
Calgary , Alberta
Denmark (1)
Herlev og Gentofte Hospital
Herlev
Finland (1)
Docrates Syopasairaala
Helsinki
France (1)
Centre Hospitalier Regional Universitaire - Hopital Morvan
Brest
Greece (1)
Agios Savvas Anticancer Hospital
Athens
Hungary (1)
Semmelweis Egyetem
Budapest
Italy (1)
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati
Avellino
Japan (1)
Aichi Cancer Center Hospital
Nagoya , Aichi-ken
Netherlands (1)
Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis
Amsterdam
Poland (1)
Uniwersyteckie Centrum Kliniczne
Gdansk
Russia (1)
Clinical hospital 2, Group of companies medsi
Moscow
South Korea (1)
Chungbuk National University Hospital
Cheongju-si, Chungcheongbuk-do
Spain (1)
Hospital Regional Universitario de Malaga
Málaga , AndalucÃ-a
Sweden (1)
Gavle Sjukhus
Gävle
Taiwan (1)
China Medical University Hospital
Taichung
United Kingdom (1)
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
БГ